STAR

Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES

Source text: [ID:]

Further company coverage: SRID.NS

(([email protected];;))

June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED

Source text: ID:nBSE8QfTWN

Further company coverage: SRID.NS

(([email protected];;))

** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees

** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%

** SRID says it beat its forecast on all key metrics, including revenue, EBITDA

** Adds, growth led by US business growth, up 21.8% Y/Y and new launches

** Stock up ~5.5% YTD, eyes extending rally for a fourth session

($1 = 85.9340 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB

Source text: ID:nNSEbkyWGB

Further company coverage: SRID.NS

(([email protected];))

March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA

Source text: ID:nBSE5Grkf4

Further company coverage: SRID.NS

(([email protected];))

** Shares of Indian Pharma companies which make drugs for HIV rise between 2% to 13%

** U.S. decides to resume funding HIV treatment after pausing the foreign aid on Jan. 26

** Strides Pharma SRID.NS up 13%, Laurus Labs LAUL.NS rise 8%, Aurobindo Pharma ARBN.NS rise 3% and Cipla CIPL.NS up 2%

** Strides, which reported 77% rise in Q3 profit earlier in the day, is top gainer on the pharma index .NIPHARM which is up 1%

** Since Jan. 26, LAUL down 10% and SRID fell 5% as of last close, while SRID was largely flat and Cipla was up 1%

(Reporting by Nishit Navin)

(([email protected];))

Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS

• STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO

Source text: ID:nBSEbPMJqh

Further company coverage: SRID.NS

(([email protected];;))

Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE

• FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES

Source text: ID:nNSE69gFWY

Further company coverage: SRID.NS

(([email protected];;))

Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION

Source text for Eikon: ID:nBSE3YQjWM

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees

** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago

** Rev from ops rose 20% Y/Y

** More than 385,000 shares change hands, 1.1x its 30 day avg

** Stock has surged over two-fold so far this year

($1 = 84.0510 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES

• COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION

Source text for Eikon: ID:nBSE7MJ6X7

Further company coverage: SRID.NS

(([email protected];;))

Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY

• ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE

Further company coverage: SRID.NS

(([email protected];))

Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG

Source text for Eikon: ID:nBSEf6hKM

Further company coverage: SRID.NS

(([email protected];))

Sept 6 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - GETS USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLET

Source text for Eikon: ID:nBSE3w42Yc

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma SRID.NS up 4% at record high of 1,020.75, highest since April 2017

** Co reported Q1 profit of 702 mln rupees vs 102.4 mln rupees year ago

** Stk up 57.4% YTD vs 28.4% gains in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

May 22 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD- INCREMENTAL GROWTH TO BE VISIBLE IN H2FY25 IN US MARKET

• STRIDES PHARMA SCIENCE - AIMING FOR AN EBITDA OF 9.50 BILLION RUPEES – 10 BILLION RUPEES FOR FY25

• STRIDES PHARMA SCIENCE LTD- AIMING FOR NET DEBT REDUCTION OF 5 BILLION RUPEES IN FY25

• STRIDES PHARMA SCIENCE LTD- CONTINUING CAPEX OF 1,500 MILLION RUPEES - 2,000 MILLION RUPEES IN FY25

• STRIDES PHARMA SCIENCE - SEES US BUSINESS REVENUE TO BE IN RANGE OF $285- $300 MILLION FOR FY25

• STRIDES PHARMA SCIENCE LTD- AIMING FOR REVENUE IN RANGE OF $175-190 MILLION FOR ONESOURCE IN FY25

• STRIDES PHARMA SCIENCE LTD- AIMING FOR EBITDA IN RANGE OF $60-$65 MILLION FOR ONESOURCE IN FY25

• STRIDES PHARMA SCIENCE - SEES EBITDA MARGIN TO BE IN THE RANGE OF 20%- 22% FOR FY25

• STRIDES PHARMA SCIENCE LTD- AIM TO ACHIEVE $400 MILLION IN THE NEXT 3 YEARS IN US BUSINESS

• STRIDES PHARMA SCIENCE - SEES CONTINUING BUSINESS REVENUE TO GROW AT 12-15% YOY FOR FY25

Source text for Eikon: [ID:]

Further company coverage: SRID.NS

(([email protected];))

May 10 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - STRIDES RECEIVES USFDA APPROVAL FOR SEVELAMER CARBONATE TABLETS, 800 MG

Source text for Eikon: [ID:]

Further company coverage: SRID.NS

(([email protected];))

April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG

Source text for Eikon: ID:nBSE6GNL4V

Further company coverage: SRID.NS

(([email protected];))

March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA

Source text for Eikon: ID:nBSE15mLyg

Further company coverage: SRID.NS

(([email protected];;))

March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL

Source text for Eikon: ID:nBSE7qH1Gm

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS up 2.3%

** Stock roses as much as 4.8% to day's high of 834.6 rupees

** Pharmaceutical co's unit received U.S. FDA approval for Gabapentin Tablets USP, 600 mg and 800 mg

** It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain

** The product is bioequivalent to the reference-listed drug Neurontin Tablets, 600 mg and 800 mg, from Viatris Specialty LLC, co added

** The drug will be manufactured at Strides' Puducherry facility

** Stock is up 25.4% so far this year; after rising 85.6% in 2023

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• INDIA’S STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL NET PROFIT 496.7 MILLION RUPEES VERSUS LOSS 800.3 MILLION RUPEES

• STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.38 BILLION RUPEES VERSUS 8.65 BILLION RUPEES

Source text for Eikon: ID:nBSE2NPxSM

Further company coverage: SRID.NS

(([email protected];))

Jan 11 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT ENTERED INTO A SHARE PURCHASE AGREEMENT FOR DIVESTMENT OF 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY

• DEAL FOR EURO 200,000

Source text for Eikon: ID:nBSE3vsMl7

Further company coverage: SRID.NS

(([email protected];))

Jan 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH

Source text for Eikon: ID:nBSEb0zDJ7

Further company coverage: SRID.NS

(([email protected];;))

Dec 21 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT AVAILED CREDIT FACILITY FROM A DIVISION OF INVESTEC BANK, SOUTH AFRICA

• UNIT AVAILED CREDIT FACILITY FOR THEIR WORKING CAPITAL REQUIREMENTS

Further company coverage: SRID.NS

(([email protected];))

Dec 1 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• LAUNCHES ICOSAPENT ETHYL ACID SOFT GEL CAPSULES IN PARTNERSHIP WITH AMNEAL

Source text for Eikon: [ID:]

Further company coverage: SRID.NS

(([email protected];))

** Shares of pharmaceutical company Strides Pharma Science SRID.NS rise as much as 3.1% to 502 rupees

** SRID says its unit got U.S. FDA approval for Generic Suprep Bowel Prep Kit - oral solution of sodium sulphate, potassium sulphate and magnesium sulphate oral solution

** Stock up 41.8% YTD, including day's gains, last up ~2%

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

** Shares of Strides Pharma Science SRID.NS rise as much as 3.84% to 509.40 rupees apiece

** Rise after drugmaker's unit receives approval from U.S. FDA for drug used to treat seizures, called Levetiracetam Oral solution

** Drug has a market size of $55 million, according to analytics firm IQVIA

** Drug to be made in SRID's Bengaluru facility

** Trading volume is 504,528 shares as of 11:44 a.m. IST, 1.3x the 30-day avg - LSEG data

** SRID shares up 43% YTD, including today's gains, compared to 26.4% rise in pharma index .NIPHARM

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Strides Pharma Science SRID.NS up as much as 3.54% at 515.90 rupees

** Drugmaker said on Friday that its unit has entered into agreement with Rxilient Biohub Pte to sell its manufacturing facility in Singapore for $15 mln

** The sale, expected to close in Q3FY24, will help reduce annual costs by ~$9m - co filing

** Proceeds from the transaction will be utilized for debt reduction, SRID added

** Stock last up 2.68%, taking YTD gains to 46.42%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))